Trial Profile
Assessment of safety, efficacy, PK and PD of BG9924 in RA patients who have had an inadequate response to conventional DMARD therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Baminercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RESPOND; RESPOND-EXT
- Sponsors Biogen
- 16 Oct 2009 Preliminary results were presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
- 09 Jan 2009 Extension study status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Jan 2009 Extension study status changed from recruiting to discontinued as reported by ClinicalTrials.gov.